Cargando…

Identifying protein–protein interactions in somatic hypermutation

Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody–antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas “pure” biochemical approaches have been far les...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, Myron F., Scharff, Matthew D.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213056/
https://www.ncbi.nlm.nih.gov/pubmed/15710655
http://dx.doi.org/10.1084/jem.20050161
_version_ 1782148815775596544
author Goodman, Myron F.
Scharff, Matthew D.
author_facet Goodman, Myron F.
Scharff, Matthew D.
author_sort Goodman, Myron F.
collection PubMed
description Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody–antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas “pure” biochemical approaches have been far less prominent, but change appears imminent. Here we comment on how, when, and why biochemistry is likely to emerge from the shadows and into the spotlight to elucidate how the somatic mutation of antibody variable (V) regions is generated.
format Text
id pubmed-2213056
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22130562008-03-11 Identifying protein–protein interactions in somatic hypermutation Goodman, Myron F. Scharff, Matthew D. J Exp Med Commentary Somatic hypermutation (SHM) in immunoglobulin genes is required for high affinity antibody–antigen binding. Cultured cell systems, mouse model systems, and human genetic deficiencies have been the key players in identifying likely SHM pathways, whereas “pure” biochemical approaches have been far less prominent, but change appears imminent. Here we comment on how, when, and why biochemistry is likely to emerge from the shadows and into the spotlight to elucidate how the somatic mutation of antibody variable (V) regions is generated. The Rockefeller University Press 2005-02-21 /pmc/articles/PMC2213056/ /pubmed/15710655 http://dx.doi.org/10.1084/jem.20050161 Text en Copyright © 2005, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentary
Goodman, Myron F.
Scharff, Matthew D.
Identifying protein–protein interactions in somatic hypermutation
title Identifying protein–protein interactions in somatic hypermutation
title_full Identifying protein–protein interactions in somatic hypermutation
title_fullStr Identifying protein–protein interactions in somatic hypermutation
title_full_unstemmed Identifying protein–protein interactions in somatic hypermutation
title_short Identifying protein–protein interactions in somatic hypermutation
title_sort identifying protein–protein interactions in somatic hypermutation
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213056/
https://www.ncbi.nlm.nih.gov/pubmed/15710655
http://dx.doi.org/10.1084/jem.20050161
work_keys_str_mv AT goodmanmyronf identifyingproteinproteininteractionsinsomatichypermutation
AT scharffmatthewd identifyingproteinproteininteractionsinsomatichypermutation